TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
An October 21 psychiatry roundup reported a sham-controlled pilot trial in which one 10-minute transcranial ultrasound session was linked to a modest reduction in delusion scores among people with schizophrenia. It also highlighted research identifying a circadian subtype in about one-quarter of adults with severe, recurrent depression and a report that safeguards for people with eating disorders remain limited amid wider GLP-1 use.
A psychiatry news roundup published October 21 highlighted a pilot trial in which a single, 10-minute transcranial ultrasound session produced a modest but statistically significant reduction in delusion scores among people with schizophrenia, as well as research on depression linked to disrupted body clocks and concerns about eating-disorder safeguards during the GLP-1 drug boom. The findings point to active research and policy questions, not established new treatments or proof that the drugs cause eating disorders.
The ultrasound finding came from a sham-controlled pilot trial reported in npj Acoustics. Participants received one 10-minute session, and researchers recorded a modest but significant drop in delusion scores. The roundup did not provide the number of participants, the size of the effect, how long any change lasted, or whether participants experienced adverse effects. A pilot result does not establish that ultrasound is safe or effective as routine schizophrenia care.
A cross-sectional study in the British Journal of Psychiatry found that roughly one-quarter of adults with severe, recurrent depressive disorders had what researchers described as a circadian subtype. It was characterized by disrupted 24-hour sleep-wake cycles. Because the study was cross-sectional, it describes a pattern observed in the group; it does not establish what caused the pattern or whether treating circadian disruption would improve depression.
The roundup also cited a New York Times report that few safeguards are in place for people with eating disorders amid growing use of GLP-1 drugs. It did not specify which safeguards are absent or provide evidence that the medicines cause eating disorders. Separately, the CDC’s 2025 Youth Risk Behavior Survey found 40.5% of high school students reported binge eating on at least one day in the previous 30 days, while 17.2% reported it on three or more days. Those figures describe survey responses, not a diagnosis or a link to GLP-1 treatment.
Potential New Tools and Treatment Risks
The ultrasound result is of interest because it suggests a brain-stimulation approach may affect a symptom associated with schizophrenia. But the evidence described is early: one brief session in a pilot trial cannot show whether changes persist, apply to a broader patient population, or compare favorably with existing care. Readers should not interpret it as a treatment recommendation.
The circadian finding may help researchers examine whether sleep-wake disruption marks a meaningful pattern among some people with recurrent depression. The eating-disorder reporting raises a different concern: as GLP-1 medicines become more widely used, patients with eating disorders may need protections suited to their circumstances. The source material does not establish what clinical guidance or safeguards should be adopted, or quantify the extent of risk.
transcranial ultrasound device for schizophrenia
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Three Findings at Different Stages
The items appeared together in MedPage Today’s psychiatry roundup, which combined research reports, public-health data and other mental-health news. They are not parts of one study and should not be treated as evidence for a single conclusion. The ultrasound work was a pilot experiment; the depression research was cross-sectional; the eating-disorder item summarized a news report about safeguards.
The roundup also reported that one-third of high school students experienced persistent sadness or hopelessness, with prevalence higher among females, according to the CDC’s 2025 survey. The survey’s binge-eating figures refer to the 30 days before respondents answered. Neither set of statistics establishes that GLP-1 medicines contributed to the reported experiences.
“A single, 10-minute transcranial ultrasound session led to a modest but significant drop in delusion scores among people with schizophrenia in a sham-controlled pilot trial.”
— MedPage Today, summarizing the npj Acoustics pilot trial
Trial Limits and Safeguard Details
Key details about the ultrasound trial remain unavailable in the roundup, including its size, participant characteristics, effect magnitude, duration of improvement and side effects. It is also unclear whether researchers plan larger trials or repeated-session testing. The reported result is an early signal, not evidence of lasting benefit.
For the circadian study, the summary does not explain how researchers defined or measured the subtype, or whether the pattern predicts treatment response. For GLP-1s and eating disorders, the roundup gives no specific account of which safeguards are missing, which patients are most affected, or what evidence connects medication use with eating-disorder outcomes. The CDC survey figures are not evidence of such a connection.
Evidence Needed Before Practice Changes
Further, larger and longer-term studies would be needed to determine whether ultrasound can reliably reduce delusions, how long any benefit lasts, and what risks may accompany treatment. Researchers would also need to test whether the circadian pattern can be identified consistently and whether it changes clinical outcomes.
On GLP-1s, the source material does not identify a specific policy or clinical guidance announcement as the next step. Further reporting and evidence would need to clarify the safeguards under discussion and how clinicians should address eating-disorder concerns when prescribing these medicines. Until those details emerge, the roundup supports treating the issue as an open question, not as a proven drug effect.
Key Questions
Does the ultrasound trial show that ultrasound treats schizophrenia?
No. The report describes a pilot trial with a modest reduction in delusion scores after one session. It does not establish lasting benefit, safety for routine use, or effectiveness across a wider population.
What does ‘circadian subtype’ mean in the depression study?
Researchers used the term for a pattern of severe, recurrent depression associated with disrupted 24-hour sleep-wake cycles. The cross-sectional finding does not show that the disruption causes depression.
Did the CDC survey link binge eating to GLP-1 drugs?
No such link is reported. The CDC figures describe high school students’ survey responses about binge eating in the previous 30 days; they do not establish a connection to GLP-1 medicines.
What is known about eating-disorder safeguards for GLP-1 users?
The roundup cited a New York Times report saying few safeguards exist for patients with eating disorders amid wider GLP-1 use. It did not specify which safeguards are lacking or quantify the risks.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
